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Abstract
Background: Though influenza vaccines are the cornerstone of medical interventions aimed at
protecting individuals against epidemic influenza, their effectiveness in HIV infected individuals is not
certain. With the recent detection of influenza strains in countries with high HIV prevalence rates,
we aimed at evaluating the current evidence on the efficacy and clinical effectiveness of influenza
vaccines in HIV-infected individuals.
Methods: We used electronic databases to identify studies assessing efficacy or effectiveness of
influenza vaccines in HIV patients. We included studies that compared the incidence of culture- or
serologically-confirmed influenza or clinical influenza-like illness in vaccinated to unvaccinated HIV
infected individuals. Characteristics of study participants were independently abstracted and the
risk difference (RD), the number needed to vaccinate to prevent one case of influenza (NNV) and
the vaccine effectiveness (VE) computed.
Results: We identified six studies that assessed the incidence of influenza in vaccinated HIV-
infected subjects. Four of these studies compared the incidence in vaccinated versus unvaccinated
subjects. These involved a total of 646 HIV-infected subjects. In all the 4 studies, the incidence of
influenza was lower in the vaccinated compared to unvaccinated subjects with RD ranging from -
0.48 (95% CI: -0.63, -0.34) to -0.15 (95% CI: -0.25, 0.05); between 3 and 7 people would need to
be vaccinated to prevent one case of influenza. Vaccine effectiveness ranged from 27% to 78%. A
random effects model was used to obtain a summary RD of -0.27 (95%CI: -0.42, -0.11). There was
no evidence of publication bias.
Conclusion: Current evidence, though limited, suggests that influenza vaccines are moderately
effective in reducing the incidence of influenza in HIV-infected individuals. With the threat of a
global influenza pandemic, there is an urgent need to evaluate the effectiveness of influenza vaccines
in trials with a larger number of representative HIV-infected persons.
Background
Influenza viruses are common causes of acute respiratory
illnesses [1]. The recent spread of the H5N1 type in Asia
has alerted the public health community to the threat of
an influenza pandemic similar to those the world experi-
enced in 1918, 1957 and 1968 [2]. With an estimated
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of 2005[3], it is imperative to evaluate the potential
impact of the HIV epidemic on an influenza pandemic
and influenza control measures.
Influenza vaccines are the cornerstone of medical inter-
ventions aimed at protecting individuals against epidemic
influenza. The efficacy of influenza vaccines in HIV
infected individuals remains poorly defined. Theoretical
safety concerns stem primarily from transient increases in
HIV viral loads following influenza vaccination observed
in some studies [4-10], although the clinical significance
of this phenomenon is unclear. Furthermore, the efficacy
of influenza vaccines may be compromised by reduced
antibody responses observed in some HIV infected indi-
viduals [4,11-16]. Despite these issues, the US Center for
Disease Control and Prevention (CDC) recommends
influenza vaccines in HIV-infected individuals [17].
Though this recommendation may be justified by an
increased susceptibility to influenza, prolonged viral rep-
lication and shedding as well as longer duration of influ-
enza symptomatology and higher influenza-related
mortality rates in HIV infected individuals [18], the effi-
cacy and clinical effectiveness of influenza vaccines in
HIV-infected individuals is not established. In this paper,
the current evidence is reviewed to determine the efficacy
and effectiveness of influenza vaccines in preventing
influenza illness in HIV infected individuals.
Methods
Search strategy and selection criteria
We searched for all trials that assessed the efficacy or effec-
tiveness of influenza vaccine in HIV-infected individuals
of all ages. Databases searched included MEDLINE (1966
to December 2005), OVID (1966 to December 2005),
EMBASE (1974 to December 2005), WHO website,
Cochrane Acute Respiratory Infections (ARI) Group Trials
Register, Cochrane Central Register of Controlled Trials
(CENTRAL) and the clinical trials register (clinicaltri-
als.gov). We used the following key search terms: influ-
enza vaccine, flu vaccine, HIV, influenza cases, efficacy
and effectiveness. We included studies in the analysis if
they assessed the efficacy or effectiveness of any influenza
vaccine given in any dose, preparation, or time schedule;
compared with placebo or with no intervention and in
any geographical location in HIV infected individuals.
Though eligible for inclusion, we did not identify any
study published in any language other than English. We
evaluated the efficacy of the vaccine, using as outcome the
occurrence of culture- or serologically-confirmed influ-
enza, and effectiveness using as outcome, clinical influ-
enza-like illness during the influenza season following
vaccine administration. Randomized clinical trials, cohort
and case-control studies were eligible for inclusion in this
analysis. Studies had to report enough data to estimate
vaccine efficacy for prevention of clinically and/or labora-
tory confirmed cases of influenza.
Two authors independently applied the inclusion criteria
to identify all relevant articles which were also reviewed
for further references. We extracted the following informa-
tion from the identified studies: year of study, location,
study design, type of vaccine, patients' characteristics, and
outcomes. When more than one case definition of influ-
enza was used, we extracted data for all outcome defini-
tions. If relevant information regarding the study design,
patient characteristics or outcomes was unavailable, or if
doubt existed about duplicate publications, we contacted
authors to obtain the necessary information. We resolved
discrepancies by consensus.
Statistical analysis
All statistical calculations were performed using STATA,
Version 8.0 (StataCorp, College Station, Texas, USA). We
computed for each study, the risk difference (RD),
number needed to vaccinate (NNV) and vaccine efficacy/
effectiveness. Pooled estimates of the RD were obtained
using fixed and random effects model by the DerSimo-
nian and Laird method [19]. The heterogeneity chi-square
statistic was used to assess the degree of heterogeneity
between studies. Because heterogeneity tests have low
power especially with a small number of studies, we used
an alpha-level of 0.20 to reject the null hypothesis of
homogeneity. To allow for heterogeneity, the summary
estimate was obtained using a random effect model. We
could not explore the sources of heterogeneity by con-
ducting subgroup analyzes or meta-regression because of
the small number of studies identified. We assessed the
presence of publication bias by examining Funnel plots
for asymmetry, and using the Begg's rank correlation test
and Egger regression asymmetry test [20-23].
Results
We identified 6 studies that reported the risk of influenza
in HIV-infected individuals. However, for this meta- anal-
ysis we only included 4 studies, because one study was a
duplicate [24] and the other study did not have enough
information to calculate an effectiveness measure [25]. In
the latter study, 72 HIV-infected individuals were vacci-
nated with a single dose of 15 μg of the 1998–1999 season
influenza vaccine (A/Sydney/5/97 (H3N2), A/Beijing/
262/95 (H1N1), B/Beijing/184/93). There were 18 cases
(25%) of influenza-like illness characterized by abrupt
onset of fever (> 39°C), myalgia and sore throat. Since all
of the individuals who were HIV positive were vaccinated,
it was impossible to obtain an effectiveness measure and
therefore we did not include the study in the meta-analy-
sis.Page 2 of 6
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included in our analysis. These studies involved a total of
646 study participants. The studies were conducted in the
USA (n = 2), Japan (n = 1) and Italy (n = 1), between 1995
and 2002. The age of the participants ranged from 20 to
78 years. We did not identify studies that included HIV-
infected children as participants. The majority of the study
participants were male comprising 82% (n = 532) of all
the subjects included in this meta-analysis. Except for one
study, which reported a median CD4 cell count of 149
cells/μl [4], the majority of individuals in the other studies
were not severely immunocompromised with the median
CD4 cell count being above 400 cells/μl. The proportion
of individuals receiving highly active antiretroviral ther-
apy (HAART) across the studies ranged from 56% to 96%.
All of the studies were conducted in a health facility set-
ting and the follow-up period ranged from 3 months to 2
years. Only one study [26] randomly assigned study par-
ticipants to vaccine or placebo groups and masked the
subjects from the treatment allocation. The rest of the
studies did not randomly assign individuals and did not
provide a placebo for the control arm. Three studies used
a dose of 15 μg of vaccine but one study did not report the
dosage of vaccine used [4]. The vaccines in all the studies
included more than one viral strain.
Table 2 shows the total number of subjects in the vaccine
and in the control groups and the number of events in
each group for each study. Cases of influenza occurred less
frequently in the vaccinated group compared to the non-
vaccinated group. All but one study reported a statistically
significant protection against influenza by vaccine. The
RD ranged from -0.15 (95% confidence interval -0.25 to -
0.05) to -0.48 (95% confidence interval -0.63 to -0.34)
(Figure 1). In these studies, between 3 and 7 HIV-infected
subjects needed to be vaccinated to prevent one case of
influenza. However, vaccine effectiveness ranged from
27% to 78% (Table 2). It is worth noting that unlike the
RD, VE is a measure of the difference in risks between vac-
cinated and unvaccinated, accounting for the observed
(baseline) risk of disease in people who did not receive
vaccine. Thus, despite having the lowest RD, the study
conducted in Japan [27] had a relatively high VE of 70%.
Ranieri et al [34] only evaluated the effectiveness of vac-
cines in preventing clinical cases of flu and reported the
highest risk reduction (RD of -0.48). The other three stud-
ies [4,24,26] evaluated both the efficacy of vaccination for
prevention of laboratory confirmed (serologically and/or
by culture) cases and the effectiveness of vaccines in pre-
venting clinically confirmed cases of influenza (Table 2).
Only Tasker et al. reported the number of outcomes sepa-
rately according to the different case definitions of influ-
enza used in the study [26]. Vaccine significantly reduced
the occurrence of influenza for all the three case defini-
tions. The RD was -0.11 (95% confidence interval -0.20 to
-0.02) for cases diagnosed using viral culture; -0.20 (95%
confidence interval -0.32 to -0.07) for cases diagnosed
using a 4-fold increase in antibody titers and -0.26 (95%
confidence interval -0.39 to -0.12) for cases diagnosed
using either culture or serology. The summary effect meas-
ure of effectiveness of the vaccines included clinical and
laboratory diagnosis of flu cases. Overall, vaccinating
HIV-infected individuals resulted in a significant reduc-
Table 1: Characteristics of studies evaluating the effectiveness of influenza vaccine in HIV infected Individuals
Study, 
location and 
reference
Number of 
Patients
Study Design Age * (years) CD4 Cell 
Count**
Vaccine strains Comparator
Tasker 1999, 
USA, [26]
102 Randomized 
double blind, 
placebo 
controlled
33 403.1 A/Johannesburg/
33/94 A/Texas/
36/91 B/Harbin/
07/94)
(H3N2), (HlNl), Saline
Fine 2001, USA, 
[4]
71 Outbreak 
investigation
38 149 A/Nanchang/933/
95(H3N2), A/
Texas/36/
91(H1N1), B/
Harbin/07/94, 
York/83/
97(H3N2)
A/New None
Raineri 2005, 
Italy, [34]
145 Prospective 
nonrandomized
20–69 -- INFLEXAL V, 
Berna
None
Yamanaka 2005, 
Japan, [27]
328 Prospective 
nonrandomized
40.8 379 A/New 
Caledonia/20/99 
A/Panama/2007/
99 B/Shanton/7/
87
(H1N1), (H3N2), None
*- mean or range; **-median values (mean used when median was not reported[26])Page 3 of 6
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0.25 (95% confidence interval ranging from -0.43 to -
0.08) (Figure 1). This overall estimate should be treated
with caution as there was evidence of heterogeneity across
studies (chi-square = 14.23, p-value = 0.003).
We assessed publication bias graphically (using a funnel
plot) and statistically. The funnel plot displays a plot of
the risk difference versus the reciprocal of the standard
error. However, because of the small number of studies
included in this meta-analysis, it was difficult to visually
determine the absence or presence of asymmetry by exam-
ining this plot. Nevertheless, both the Begg's rank correla-
tion (p-value = 1.00) and Egger's regression tests (p-value
= 0.819) did not show any evidence of publication bias.
Discussion
This study represents the first published systematic review
with meta-analysis of the effectiveness of influenza vac-
cines in HIV-infected persons. Although we identified a
limited number of studies, this review suggests a reduc-
tion in the incidence of influenza following vaccination.
The magnitude of the reduction is however moderate as
evidence by the vaccine effectiveness computed for each
of the studies. The vaccine effectiveness was similar to that
reported in HIV-negative individuals and in the elderly
[28,29]. Even though influenza vaccine is generally rec-
ommended for the latter, in HIV-infected persons, the
safety of vaccines in each individual needs to be consid-
ered before its administration. In HIV-infected persons,
influenza vaccines may result in an increase in HIV
plasma level and/or a reduction in CD4 cell counts. These
changes, in most cases, have been transient [30], but war-
rant serious consideration. The evidence of effect hetero-
geneity in our analysis further supports the need for
individual considerations in deciding to administer influ-
enza to each HIV-infected person. Differences in study
design, vaccine composition, or study population could
be the reason for heterogeneity. However these could not
be explored in this analysis because of the limited number
of studies identified.
Most previous studies of influenza vaccines in HIV-
infected persons focused on their immunogenicity rather
than their clinical effectiveness [11-14,24,31-33]. These
immunogenicity studies confirmed the production of pro-
tective antibodies in HIV infected persons even though
the antibody levels in HIV infected persons appear to be
lower to those in HIV-negative persons. Although the
effectiveness of vaccines is mediated by the immune
response, the presence of an immune response may not
always guarantee clinical effectiveness in preventing infec-
tion and/or reducing disease severity following infection.
The results of clinical studies reviewed here suggest that
immune response levels in some HIV-infected persons
may be sufficiently protective against clinical disease. Fur-
thermore, the highest risk reduction reported in Ranieri et
al.'s study indicates that vaccine may be more effective in
preventing clinical disease than it is in preventing infec-
tion per se.
Forest plot of studies of the effectiveness of influenza vac-cines in HIV-infected individualsigure 1
Forest plot of studies of the effectiveness of influenza vac-
cines in HIV-infected individuals.
Risk difference
-.75 -.5 -.25 0 .25
Study
Risk difference
(95% CI)
No. of events
Treatment Control
Tasker (1999) -0.26 (-0.39,-0.13) 1/55 13/47
Fine (2001) -0.17 (-0.40, 0.06) 19/42 18/29
Yamanaka (2005) -0.15 (-0.25,-0.05) 16/262 14/66
Ranieri (2005) -0.48 (-0.63,-0.34) 12/90 34/55
Overall -0.27 (-0.42,-0.11) 48/449 79/197
Heterogeneity chi-squared = 14.23 (d.f. = 3), p = 0.003, I2 = 76.8%
Test of RD=0: z = 2.28, p = 0.004
Protective vaccine Not protective vaccine
Table 2: Effectiveness of influenza vaccines in HIV-infected patients
Study Outcome Studied Vaccine Control Risk Difference 
(95% C.I.)
NNV* Vaccine 
effectiveness **
Tasker 1999 [26] Symptoms of respiratory illness, at least 4 fold 
increase in antibody titre, viral culture
16/55 23/47 -0.198 (-0.387, -
0.01)
5 41%
Fine 2001, [4] Influenza like illness or a 4 fold increase in 
antibody titers or isolation of influenza virus
19/42 18/29 -0.168 (-0.404, -
0.067)
6 27%
Raineri 2005, [34] Influenza illness 12/90 34/55 -0.485 (-0.632, -
0.337)
3 78%
Yamanaka 2005, [27] Influenza like symptoms with at least 4 fold 
increase in antibody titre or viral isolation in 
culture
16/262 14/66 -0.151 (-0.255, -
0.048)
7 71%
C.I.: Confidence Interval; NNV: * Number needed to vaccinate (= 1/RD); ** Vaccine effectiveness = 100*(1-risk ratio)Page 4 of 6
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:138 http://www.biomedcentral.com/1471-2334/6/138We only identified one randomized study. The three other
studies were liable to selection bias and/or confounding.
Due to the few number of subjects included in each study,
we were not able to assess the effect of the stage of HIV dis-
ease (HIV viral load and or CD4 levels) or antiretroviral
treatment on the effectiveness of vaccines. In addition,
because these studies were conducted in developed coun-
tries with predominantly male study populations, their
results may not be generalizable to the majority of HIV-
infected men and women who live in developing coun-
tries. With the threat of a global influenza pandemic, there
is an urgent need to evaluate the effectiveness of influenza
vaccines in a larger number of representative HIV-infected
persons throughout the world.
Conclusion
Current evidence suggests that influenza vaccines are
effective, albeit moderately, in reducing the incidence of
influenza in HIV-infected individuals. Vaccination is thus
a potentially useful intervention and should be consid-
ered in the care of HIV-infected individuals. Further stud-
ies of clinical effectiveness recruiting larger numbers of
HIV-infected subjects and in populations most affected by
HIV are, however, required.
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